

## Increased Gao expression underlies cardiac dysfunction and lethal arrhythmias accompanied with abnormal Ca<sup>2+</sup> handling

H. Inazumi<sup>1</sup>, K. Kuwahara<sup>2</sup>, Y. Kuwabara<sup>3</sup>, Y. Nakagawa<sup>1</sup>, H. Kinoshita<sup>1</sup>, K. Moriuchi<sup>1</sup>, H. Yanagisawa<sup>1</sup>, T. Nishikimi<sup>1</sup>, M. Oya<sup>2</sup>, M. Yamada<sup>2</sup>, T. Kashihara<sup>2</sup>, N. Kurebayashi<sup>4</sup>, M. Sugihara<sup>4</sup>, K. Nakao<sup>1</sup>, T. Kimura<sup>1</sup>

<sup>1</sup>Kyoto University Graduate School of Medicine, Kyoto, Japan; <sup>2</sup>Shinsyu University School of Medicine, Matsumoto, Japan; <sup>3</sup>Kyoto University Hospital, Kyoto, Japan; <sup>4</sup>Juntendo University Graduate School of Medicine, Tokyo, Japan

**Background:** We previously demonstrated that a transcriptional repressor, neuron restrictive silencer factor (NRSF), maintains normal cardiac function and electrical stability. Transgenic mice expressing a dominant-negative mutant of NRSF in their hearts (dnNRSF-Tg) exhibit systolic dysfunction with cardiac dilation and premature death due to lethal arrhythmias like human dilated cardiomyopathy (DCM). Underlying mechanisms remain to be elucidated, however.

**Purpose:** We studied underlying mechanisms by which NRSF maintains normal cardiac function to identify novel therapeutic targets for heart failure.

**Methods and results:** We generated cardiac-specific NRSF knockout mice (NRSF<sup>Cre</sup> KO) and confirmed that cardiac phenotypes of NRSF<sup>Cre</sup> KO are similar to those of dnNRSF-Tg.

cDNA microarray analysis revealed that cardiac gene expression of GNAO1 that encodes G $\alpha_o$ , a member of inhibitory G protein G $\alpha_i$  family, is increased in both dnNRSF-Tg and NRSF<sup>Cre</sup> KO ventricles.

We confirmed that GNAO1 is a direct target of NRSF through ChIP-seq analysis, reporter assay and electrophoretic mobility shift assay.

In dnNRSF-Tg, pharmacological inhibition of G $\alpha_o$  with pertussis toxin

improved systolic dysfunction and knockdown of G $\alpha_o$  by crossing with GNAO1 knockout mice improved not only systolic function but also frequency of ventricular arrhythmias and survival rates.

Electrophysiological and biochemical analysis in ventricular myocytes obtained from dnNRSF-Tg demonstrated that genetic reduction of G $\alpha_o$  ameliorated abnormalities in Ca<sup>2+</sup> handling, which include increased current density in surface sarcolemmal L-type Ca<sup>2+</sup> channel, reduced content of sarcoplasmic reticulum Ca<sup>2+</sup> and lowered peak of Ca<sup>2+</sup> transient. Furthermore, genetic reduction of G $\alpha_o$  attenuated increased phosphorylation levels of CAMKII in dnNRSF-Tg ventricles, which presumably underlies the improvement in Ca<sup>2+</sup> handling. In addition, we identified increased G $\alpha_o$  expression in ventricles of heart failure model mice induced by transverse aortic constriction and cardiac troponin T mutant DCM model mice, in both of which, genetic reduction of G $\alpha_o$  ameliorated cardiac dysfunction.

**Conclusions:** We found that increased expression of G $\alpha_o$ , induced by attenuation of NRSF-mediated repression, plays a crucial role in the progression of cardiac dysfunction and lethal arrhythmias by evoking Ca<sup>2+</sup> handling abnormality. These data demonstrate that G $\alpha_o$  is a potential therapeutic target for heart failure.

### Knockdown of Gao improved survival rate, cardiac function and arrhythmogenicity




Figure 1